Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001172187 | SCV001335168 | likely pathogenic | not provided | 2020-02-01 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001379714 | SCV001577563 | likely pathogenic | CHARGE association | 2020-04-08 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has been observed in individual(s) with clinical features of Kallmann syndrome (Invitae). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (ExAC no frequency). This sequence change replaces lysine with glutamic acid at codon 1076 of the CHD7 protein (p.Lys1076Glu). The lysine residue is highly conserved and there is a small physicochemical difference between lysine and glutamic acid. |